利培酮与氨磺必利在首发精神分裂症患者治疗中的应用

Application of Risperidone and Amisulpride in the Treatment of Firstepisode Schizophrenic Patients

目的对首发精神分裂症患者分别采用利培酮与氨磺必利进行治疗,对比两种药物的治疗效果和安全性。方法选择2015年2月—2016年12月在我院接受治疗的72例首发精神分裂症患者参与研究,随机将患者分成两组,A组36例,B组36例,A组患者采用利培酮进行治疗,B组患者采用氨磺必利进行治疗,对比两组患者的阳性与阴性量表评分,并查看两组患者不良反应的发生情况。结果经过治疗,两组患者的阳性与阴性量表评分均有了不同程度的改善,且B组患者优于A组患者(P<0.05)。两组患者的不良反应发生率经过对比差异无统计学意义。结论针对首发精神分裂症患者可采用利培酮或氨磺必利进行治疗,治疗效果显著,安全性高,且氨磺必利的治疗效果优于利培酮。

Objective To compare the safety and efficacy of amisulpride and risperidone in the treatment of first-episode schizophrenia.Methods 72 patients with first episode schizophrenia were selected as the study subjects from February 2015 to December 2016,and divided into two groups according to different treatment drugs,36 cases in each group.Patients in group A were treated with risperidone and group B was treated with amisulpride,and the positive and negative symptom scores and the incidence of adverse events were compared between the two groups.Results After treatment,positive and negative scale scores in both groups of patientswere improved to varying degrees,and B group was significantly better than patients in group A（P〈0.05）.There was no significant difference in the incidence of adverse events between the two groups.Conclusion Amisulpride and risperidone are safe and effective in the treatment of first-episode schizophrenia,and amisulpride is superior to risperidone.